Free Trial

GSK (GSK) Stock Forecast & Price Target

GSK logo
GBX 1,503.50 -14.00 (-0.92%)
As of 12:38 PM Eastern

GSK - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
1
Hold
2
Buy
1

Based on 4 Wall Street analysts who have issued ratings for GSK in the last 12 months, the stock has a consensus rating of "Hold." Out of the 4 analysts, 1 has given a sell rating, 2 have given a hold rating, and 1 has given a buy rating for GSK.

Consensus Price Target

GBX 1,637.50
According to the 4 analysts' twelve-month price targets for GSK, the average price target is GBX 1,637.50. The highest price target for GSK is GBX 2,100, while the lowest price target for GSK is GBX 1,400. The average price target represents a forecasted upside of 8.91% from the current price of GBX 1,503.50.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for GSK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for GSK and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

GSK Analyst Ratings Over Time

TypeCurrent Forecast
9/12/24 to 9/12/25
1 Month Ago
8/13/24 to 8/13/25
3 Months Ago
6/14/24 to 6/14/25
1 Year Ago
9/13/23 to 9/12/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
1 Buy rating(s)
5 Buy rating(s)
5 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
0 Hold rating(s)
1 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
Consensus Price TargetGBX 1,637.50GBX 1,612.50GBX 1,862.50GBX 1,805.71
Consensus RatingHoldHoldModerate BuyModerate Buy

GSK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

GSK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

GSK Stock vs. The Competition

TypeGSKMedical Companies
Consensus Rating Score
2.00
2.78
Consensus RatingHoldModerate Buy
News Sentiment Rating
Positive News

See Recent GSK News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
8/27/2025Shore Capital
1 of 5 stars
 Reiterated RatingBuyGBX 2,100+41.89%
8/4/2025JPMorgan Chase & Co.
2 of 5 stars
 Lower TargetUnderweightGBX 1,460 ➝ GBX 1,400+0.68%
7/31/2025Deutsche Bank Aktiengesellschaft
3 of 5 stars
 Reiterated RatingHoldGBX 1,450+1.29%
7/18/2025Berenberg Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingHoldGBX 1,600+17.69%
7/5/2024Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower TargetBuyGBX 2,120 ➝ GBX 1,900+24.79%
6/27/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingBuyGBX 2,100+38.25%
5/7/2024Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingEqual WeightGBX 1,725-1.96%
9/25/2023Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetGBX 1,440 ➝ GBX 1,585+3.39%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 11:07 PM ET.


Should I Buy GSK Stock? GSK Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, September 9, 2025. Please send any questions or comments about these GSK pros and cons to contact@marketbeat.com.

GSK
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in GSK plc:

  • The current stock price is around $19.31, showing a recent increase, which may indicate positive market sentiment towards GSK plc.
  • GSK plc has received a "buy" rating from Shore Capital, suggesting that analysts believe the stock has strong potential for growth.
  • The company reported a return on equity of 18.08%, indicating effective management and profitability relative to shareholder equity.
  • GSK plc has a market capitalization of approximately £58 billion, reflecting its significant size and stability in the pharmaceutical industry.
  • Recent insider purchases, including shares bought by Julie Brown, may signal confidence in the company's future performance.

GSK
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in GSK plc for these reasons:

  • The company has a relatively high debt-to-equity ratio of 114.64, which may indicate financial risk and reliance on debt for growth.
  • GSK plc's net margin of 8.02% suggests that profitability could be a concern, as it indicates the percentage of revenue that remains as profit after expenses.
  • Some analysts have issued "hold" ratings, indicating uncertainty about the stock's future performance compared to its current price.
  • Recent price targets from analysts vary significantly, with some suggesting a lower target, which may reflect differing opinions on the company's growth prospects.
  • The stock has experienced fluctuations, with a 52-week high of around $22.75, indicating potential volatility that could affect investor returns.

GSK Forecast - Frequently Asked Questions

According to the research reports of 4 Wall Street equities research analysts, the average twelve-month stock price forecast for GSK is GBX 1,637.50, with a high forecast of GBX 2,100 and a low forecast of GBX 1,400.

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GSK in the last twelve months. There is currently 1 sell rating, 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GSK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GSK, but not buy additional shares or sell existing shares.

According to analysts, GSK's stock has a predicted upside of 8.91% based on their 12-month stock forecasts.

GSK has been rated by research analysts at Berenberg Bank, Deutsche Bank Aktiengesellschaft, JPMorgan Chase & Co., and Shore Capital in the past 90 days.

Analysts like GSK less than other "medical" companies. The consensus rating for GSK is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how GSK compares to other companies.


This page (LON:GSK) was last updated on 9/12/2025 by MarketBeat.com Staff
From Our Partners